Galdu-irabazien kontua
APYX MEDICAL CORP
APYX
Errendimenduaren laburpena
Egin klik taulako edozein lerrotan grafikoan gehitzeko
milioika USDtan
| Neurria | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Dec 31, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Diru-sarrerak
|
- | - | 52.35 | 44.51 | 48.52 | 27.71 | 28.24 | 16.69 | 38.88 | 36.63 | 29.52 | 27.68 | 23.66 | 27.67 | 25.41 |
|
Diru-sarreren kostua
|
19.80 | 18.74 | 18.59 | 15.38 | 14.92 | 10.21 | 9.14 | 5.89 | 19.12 | 18.71 | 16.96 | 18.69 | 14.46 | 16.34 | 14.68 |
|
Irabazi gordina
|
33.04 | 29.36 | 33.76 | 29.13 | 33.60 | 17.50 | 19.09 | 10.79 | 19.76 | 17.92 | 12.56 | 8.99 | 9.20 | 11.33 | 10.73 |
|
Ustiapen-gastuak
|
40.00 | 48.21 | 53.71 | 52.69 | 48.05 | 37.59 | 39.96 | 24.39 | 25.03 | 21.71 | 10.58 | 8.10 | 6.15 | 5.67 | 5.54 |
|
Ikerketa eta garapena
|
3.40 | 5.10 | 4.84 | 4.54 | 4.32 | 3.92 | 3.73 | 2.47 | 2.46 | 2.62 | 2.16 | 1.42 | 1.26 | 1.33 | 1.20 |
|
Salmentak, orokorrak eta administratiboak
|
15.80 | 18.86 | 22.20 | 20.48 | 18.62 | 11.69 | 13.70 | 9.44 | 11.37 | 8.57 | 8.42 | 6.69 | 4.89 | 4.34 | 4.35 |
|
Beste ustiapen-gastu batzuk
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
Ustiapen-irabaziak
|
-6.96 | -18.85 | -19.95 | -23.56 | -14.45 | -20.08 | -20.87 | -13.60 | -5.27 | -3.79 | 1.98 | 0.89 | 3.04 | 5.66 | 5.19 |
|
Ez-ustiapeneko diru-sarrerak
|
-4.39 | -4.46 | 1.33 | -0.65 | 0.37 | -0.67 | -1.03 | -0.33 | -0.05 | 0.09 | 7.33 | 14.18 | 9.00 | 4.83 | 5.16 |
|
Interesen diru-sarrerak
|
1.11 | 1.61 | 0.92 | 0.16 | 0.01 | 0.24 | 1.39 | 0.62 | - | - | - | - | - | - | - |
|
Interesen gastuak
|
- | - | 2.48 | 0.02 | 0.01 | 0.05 | 0.01 | 0.10 | - | - | - | - | - | - | - |
|
Beste ez-ustiapeneko diru-sarrerak/gastuak
|
- | -0.16 | -4.02 | 0.65 | -0.37 | 0.67 | 1.03 | 0.33 | 0.05 | -0.09 | - | - | -2.29 | -0.21 | 0.05 |
|
Zerga aurreko irabazia
|
6.69 | 1.97 | -21.28 | -22.91 | -14.82 | -19.41 | -19.84 | -13.27 | -5.22 | -3.89 | -5.35 | -13.29 | -5.95 | 0.83 | 0.03 |
|
Zerga-gastua
|
0.38 | 0.16 | -2.57 | 0.27 | 0.35 | -7.51 | -0.13 | -3.78 | -0.16 | 0.06 | 0.03 | 4.00 | -1.61 | 0.83 | 0.03 |
|
Partaidetza ez-kontrolatzailea
|
0.11 | -0.10 | -0.14 | -0.09 | -0.03 | -0.01 | - | - | - | - | - | - | - | - | - |
|
Irabazi garbia
|
-11.21 | -23.46 | -18.71 | -23.18 | -15.17 | -11.90 | -19.71 | -9.49 | -5.06 | -3.95 | -5.37 | -17.28 | -4.34 | 0.00 | 0.00 |
Informazio osagarria
Akzioko datuak, eratorritakoak eta bestelakoak — ez dira galdu-irabazien kontuaren parte
milioika USDtan, bestela adierazi ezean
| Neurria | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY | Dec 31, 2015 2015 FY | Dec 31, 2014 2014 FY | Dec 31, 2013 2013 FY | Dec 31, 2012 2012 FY | Dec 31, 2011 2011 FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Amortizazioa eta balio-galera
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-6.30 | -18.25 | -19.26 | -22.67 | -13.55 | -19.20 | -20.12 | -12.93 | -4.57 | -3.06 | 2.79 | 1.62 | 3.78 | 6.41 | 5.94 |
|
Akzioko irabazia (oinarrizkoa)
|
-0.27 | -0.66 | -0.54 | -0.67 | -0.44 | - | -0.58 | 1.93 | -0.16 | -0.14 | 0.34 | -1.03 | -0.25 | 0.04 | 0.01 |
|
EPS diluitua
|
- | - | -0.54 | -0.67 | -0.44 | - | -0.58 | 1.86 | -0.17 | -0.15 | 0.24 | -1.03 | -0.25 | 0.03 | 0.01 |
|
Akzioen batez besteko haztatua
|
41.10 | 35.54 | 34.62 | 34.52 | 34.33 | - | 34.07 | 33.19 | 31.42 | 27.43 | 24.33 | 0.02 | 0.02 | 17.63 | 17.60 |
|
Akzioen batez besteko haztatu diluitua
|
- | - | 34.62 | 34.52 | 34.33 | - | 34.07 | 34.37 | 31.43 | 27.45 | 27.75 | 0.02 | 0.02 | 17.79 | - |
|
Irabazi globala
|
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |